View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
January 28, 2022

UCB enhances epilepsy portfolio with Zogenix acquisition

By acquiring Zogenix, UCB has obtained Fintepla, an approved drug for the treatment of seizures associated with Dravet syndrome.

By GlobalData Healthcare

On 19 January, UCB announced that it had acquired Zogenix for $1.9bn in a bid to bolster its epilepsy portfolio by adding Fintepla (fenfluramine), a marketed drug for the treatment of seizures associated with Dravet syndrome, a rare form of childhood epilepsy. Having gained a newly marketed product for patients with rare and difficult-to-treat pediatric orphan epilepsy syndromes, this deal continues to expand UCB’s extensive therapeutic offering in the epilepsy market.

With the acquisition of Zogenix, UCB has obtained Fintepla, an FDA and EMA-approved drug for the treatment of seizures associated with Dravet syndrome. A new drug application for Fintepla was submitted in Japan last month, with the drug estimated to receive approval and launch later this year. The use of Fintepla is soon anticipated to expand beyond Dravet syndrome and to include Lennox-Gastaut syndrome (LGS), another severe form of epilepsy in children and adults. The FDA has accepted the supplemental new drug application for Fintepla in LGS and has granted priority review for the submission, with a Prescription Drug User Fee Act target action date of 25 March. In addition, a type II variation application has been submitted to the EMA for the use of Fintepla in LGS. The drug is currently in a Phase III clinical trial in Japan for LGS, with a primary completion date of March 2024 (NCT03355209). Fintepla is also being investigated in an ongoing Phase III trial for the treatment of patients with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder, which is characterised by seizures that begin in infancy. The trial is being conducted in the US, with a primary completion date of May next year (NCT05064878).

Fintepla competes with GW Pharmaceuticals’ Epidiolex (cannabidiol), which is approved for both LGS and Dravet syndrome. Not only does Epidiolex have a first-to-market advantage, but, as a cannabidiol-derived drug, it also has strong patient interest based on its ‘natural’ plant-derived sourcing. Despite this, key opinion leaders previously interviewed by GlobalData were impressed with the efficacy of Fintepla in paediatric patients with severe forms of epilepsy, many of whom have experienced seizures for many years. But concerns over cardiac safety could represent a barrier to uptake of Fintepla. At present, the prescription of Fintepla in the US is only available through a restricted risk evaluation and mitigation strategy programme, which is designed to manage the risks of valvular heart disease and pulmonary arterial hypertension associated with treatment. As such, echocardiogram assessments and monitoring are required before, during and after treatment. With the growing availability of products for patients with Dravet syndrome and LGS, Phase IV head-to-head clinical trials will be the key to differentiating products from one another. 

UCB has become a major player in the epilepsy market, owing to its wide variety of marketed assets launched between 2000 and 2019: Keppra, Keppra XR, Briviact, Vimpat and Nayzilam. In addition, through its acquisition of Engage Therapeutics in June 2020, UCB gained the pipeline anti-epileptic product, Staccato Alprazolam, which is now in Phase III clinical trials for the acute treatment of patients aged 12 years and older with prolonged epileptic seizures (NCT05077904). The clinical trial is being conducted in locations across the US and Japan and its primary completion date is set for July next year. UCB’s strong pipeline, coupled with the company’s vast experience in the epilepsy market, strongly indicate the company will remain a major player in the epilepsy market in the next decade and beyond.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU